EUVIMEDEUVIMED entdecken
Crossref

Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice

Aysha Mendes

Journal of Prescribing Practice · 02.05.2026 · 8 (5) · 190-192

DOI: 10.12968/jprp.2026.0051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Prescribing Practice, erschienen am 02.05.2026. Verfasst von Aysha Mendes. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aysha Mendes discusses the introduction of rozanolixizumab, which will provide more choice and targeted treatment options for generalised myasthenia gravis, with important considerations for prescribers concerning escalation, delivery and patient outcomes

Zitieren

APA

Mendes, A. (2026). Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice. Journal of Prescribing Practice, 8(5), 190-192. https://doi.org/10.12968/jprp.2026.0051

Vancouver

Mendes A. Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice. Journal of Prescribing Practice. 2026;8(5):190-192. doi:10.12968/jprp.2026.0051

BibTeX
@article{Mendes2026,
  author = {Mendes, Aysha},
  title = {Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice},
  journal = {Journal of Prescribing Practice},
  year = {2026},
  volume = {8},
  number = {5},
  pages = {190--192},
  doi = {10.12968/jprp.2026.0051}
}
Kostenlos starten →